 Hello, I would like to give you an overview of what happened in this year's EHA in Vienna regarding news to the multiple myeloma treatment. So in my view, I would say we can divide that in a bit into talking about primary diagnosis and primary therapy and relapse and disease and treatment. So starting with the primary diagnosis, the newly diagnosed myeloma, we saw late-breaking abstract on the role of high-dose malphalan therapy and the autologous stem cell transplantation. It was presented by Paul Richardson and this is a so-called determination trial which was conducted in the United States and patients were randomized. So after RVD induction, in one treatment arm patients received autologous stem cell transplantation and in one treatment arm not and all patients received consolidation and maintenance. And this trial showed that the integration of the high-dose malphalan treatment and the autologous stem cell transplantation is still both standard and remains both standard for all eligible patients in front line as it led to a significant benefit in the progression-free survival so the time to an eventual relapse. And what we also saw is that patients could stay very long on the maintenance treatment. The little maintenance was here, different unlimited and it was not stopped after one year, for example, like in the French kind of similar trial. So patients in the median after high-dose chemotherapy stayed more than 40 months on the little maintenance. This was the most important abstract in regards of frontline treatment and then there was quite a number of abstracts regarding the novel immunotherapeutics and multiple myeloma. And there were two big topics. One were the so-called bispecific T-cell engages of bispecific antibodies and the other one were for sure the T-cells which were recently approved for treatment of relapsed myeloma in Europe. Bispecifics are so far not approved, however they are tested in various indications and even in combinations. We have currently six bispecifics under evaluation in significant patient numbers and I would like to highlight that the data now on bispecifics not directed against the main target of the last year, the BCMA but against other targets we call the G-protein-coupled receptor and the bispecific is called Terkitama and the colleagues could show that this is highly active in treatment of refractory disease, response rates until 70%, they also showed that there's a distinct toxicity, the skin toxicity which might happen in quite a number of patients where we now learned also to establish supportive care and there were intriguing data showing that you can combine bispecific antibodies for example with monoclonal anti-CD38 antibodies. Despite patients had already the monoclonal anti-CD38 antibodies but that you get the immune system also with this combination even better engaged to ultimately enhance responses and we now see also that they are durable responses beyond one year of treatment. However, we also learned that bispecific antibodies might induce higher sensitivity for infections and also severe infections so this is one thing we all have to know and to notice so that in case of signs of infection early antibiotic intervention is crucial patients have to go to the doctor or the hospital if they experience signs of infection or fever and the protection against COVID is of utmost need with the vaccines but also with the protection measurements and the newly available wherever it is available it will show for the primary prophylaxis. Regarding CAR T cells there's still many efforts to further optimize and improve CAR T cells and they are continuously getting even more specific, more durable. However, what we also see is that the currently approved CAR T cells the idocaptogen vicluosal or idosal and the siltocaptogen autolosal or siltosal which is approved by currently not available in Europe show also in the longer follow-up very good data and for example the US colleagues could exactly mimic in the real world the data of the trial which led at the end to approval so with that I think the spectrum of this year's EHA is a bit shown overall a lot of data, confirming data, promising data and to my view the next big step for patients especially is the upcoming approval of bi-specific antibodies in Europe.